Drug Metabolism and Bioanalysis Letters - Volume 15, Issue 2, 2022

Coronaviruses cause disease in humans and animals. In 2019 a novel coronavirus was first characterized in Wuhan, China causing acute respiratory disease and designating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19. The COVID-19 spread to all cities of China and in 2020 to the whole world. Patients with COVID-19 may recover without medical treatment. However, some patients need m Read More

Objective: The mechanism-based inhibition of macrolide antibiotics, such as erythromycin and clarithromycin, and piperine on testosterone 6β-hydroxylation activities by cytochrome P450 (CYP) 3A4, polymorphically expressed CYP3A5, and fetal CYP3A7 were compared. Methods: 6β-Hydroxy testosterone was determined by high-performance liquid chromatography. Results: Although preincubation with erythromycin a Read More

Background: Neurological complications are most likely to be fatal and cause loss of ability to function or care for self. These include Alzheimer’s disease and cognitive impairment. The main aim of the review is to determine the effects of various drugs and their cognitive risk with the need to opt for herbal therapy as an adjuvant in treating neurological conditions like Alzheimer’s disease with lesser-known side effects. Methods Read More

The use of pharmacotherapy for improving healthcare in society is increasing. A vast majority of patients have either received subtherapeutic treatment (which could result from low pharmacokinetics) or experienced adverse effects due to the toxic levels of the drug. The medicines used to treat chronic conditions, such as epilepsy; cardiovascular diseases; oncological, neurological, and psychiatric disorders, require routine Read More

Background: Migraine is a neurological disorder and is accompanied by different painful episodes. Hence, the maintenance of a steady-state concentration of drugs can be beneficial for patients suffering from migraine. The present investigation focuses on the development of nano lipid carriers (NLCs) loaded with transdermal patches of rizatriptan benzoate to sustain the effect of the drug for the enhancement of therap Read More

Background: Identification of clinical Drug-Drug Interaction (DDI) risk is an important aspect of drug discovery and development owing to poly-pharmacy in present-day clinical therapy. Drug Metabolizing Enzymes (DME) play important roles in the efficacy and safety of drug candidates. Hence, the evaluation of a New Chemical Entity (NCE) as a victim or perpetrator is very crucial for DDI risk mitigation. ZY12201 (2-((2-(4 Read More